NMD Pharma
PrivateLast Round
Series B
Nov 15, 2023
Total Funding Raised
$170.61M
Company Overview
NMD Pharma is a biotechnology company that develops a first-in-class platform of small molecule therapies for the treatment of severe neuromuscular disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NMD Pharma Comparables
Compare NMD Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 77% | |
| Edgewise Therapeutics | 74% | |
| Epirium Bio | 70% | |
NMD Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 15, 2023 | ||||
| Series A Extension | Feb 15, 2022 | ||||
| Series A | Mar 23, 2018 | ||||
| Seed | Jun 1, 2016 |
Key People
Founding team and executive leadership
NMD Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series A Extension |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Lundbeckfonden BioCapital | Series B |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Novo Holdings | Grant, Series B, Seed, Series A, Series A Extension |
| Inkef Capital | Series B, Series A Extension, Series A |
| Capnova | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Presented SYNAPSE-CMT study data at the MDA Conference.
- Mar 10, 2026
Top-line safety and efficacy data released for ignaseclant in Phase 2a study.
NMD Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NMD Pharma's valuation, stock price, and market status.